Document Detail


A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers.
MedLine Citation:
PMID:  22681551     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Venous leg ulcers (VLUs) are the most prevalent chronic wounds in western countries with a heavy socioeconomic impact. Compression therapy is the etiologic treatment of VLU but until now no wound dressing has been shown to be more effective than another. The aim of this study was to assess the efficacy of a new dressing in the management of VLU. Adult patients presenting a noninfected VLU and receiving effective compression therapy were enrolled in this randomized, controlled, double-blind trial. The VLUs were assessed every 2 weeks for 8 weeks. The primary study outcome was the relative Wound Area Reduction (WAR, in %), and the secondary objectives were absolute WAR, healing rate, and percentage of wounds with >40% surface area reduction. One hundred eighty-seven patients were randomly allocated to treatment groups. Median WAR was 58.3% in the Lipido-Colloid Technology-Nano-OligoSaccharide Factor (TLC-NOSF) dressing group (test group) and 31.6% in the TLC dressing group (control group) (difference: -26.7%; 95% confidence interval: -38.3 to -15.1%; p = 0.002). All other efficacy outcomes were also significant in favor of the TLC-NOSF dressing group. Clinical outcomes for patients treated with the new dressing are superior to those patients treated with the TLC dressing (without NOSF compound), suggesting a strong promotion of the VLU healing process.
Authors:
Sylvie Meaume; François Truchetet; Frédéric Cambazard; Catherine Lok; Clélia Debure; Sophie Dalac; Isabelle Lazareth; Michèle-Léa Sigal; Anne Sauvadet; Serge Bohbot; Anne Dompmartin;
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-8
Journal Detail:
Title:  Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society     Volume:  -     ISSN:  1524-475X     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9310939     Medline TA:  Wound Repair Regen     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 by the Wound Healing Society.
Affiliation:
Dermatology & Geriatric Department, Rothschild University Hospital, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Investigator
Investigator/Affiliation:
B Labeille / ; Jl Perrot / ; As Lesne-Padieu / ; M Santacreu / ; E Peyron / ; M Dupin / ; Ml Dordain-Bigot / ; P Plantin / ; H Cartier / ; G Guillet / ; M Camus / ; L Machet / ; Jl Schmutz / ; E Redon / ; P Bravard / ; P Schoenlaub / ; A Vermersh / ; C Brenuchon / ; F Delesalle / ; D Thuillier / ; C Hamel-Desnos / ; J Duquesnoy / ; H Maillard / ; Y Guiguen / ; P Léger / ; P Modiano / ; D Cannone-Courivaud / ; G Safa / ; S Blaise / ; T Le Guyadec / ; Ma Pistorius / ; J Chevrant-Breton / ; J Jegou / ; Jm Bonnet-Blanc / ; Ac Ribemond-Goby / ; Mc Deroo-Berger / ; L Meunier / ; M Dandurand / ; H Paradis / ; F Augey / ; C Allombert-Blaise / ; A Pillouert-Prost / ; G Mauduit / ; Jm Bressieux / ; A Cadène / ; P Humbert / ; B Faivre / ; M Chapelon /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Involvement of ?(2) -adrenoceptors, imidazoline, and endothelin-A receptors in the effect of agmatin...
Next Document:  A glycoengineering approach to half-life extension of recombinant biotherapeutics.